Full Text View
Tabular View
No Study Results Posted
Related Studies
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
This study is currently recruiting participants.
Study NCT00673790   Information provided by Forest Laboratories
First Received: April 29, 2008   Last Updated: October 28, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypertension
Additional conditions recognized in this trial
Glucose Intolerance
Prediabetic State
More general conditions related to this trial
Cardiovascular Diseases
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Hyperglycemia
Metabolic Diseases
Vascular Diseases
Interventions listed in this trial
Nebivolol
HCTZ
Placebo
Additional drug interventions recognized in this trial
Hydrochlorothiazide
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-Antagonists
Antihypertensive Agents
Cardiovascular Agents
Diuretics
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Forest Laboratories


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services